The Horizon Europe Health Work Programme 2026-2027 is organised around six destinations. The 2027 calls opened on 29 October 2026. Single-stage topics and the first stage of two-stage topics close on 17 February 2027. The second stage of two-stage topics and the June 2027 call close on 16 September 2027.

29 October 2026

2027 calls opened

17 February 2027

Single-stage topics and stage 1 of two-stage topics close

16 September 2027

Stage 2 of two-stage topics and the June 2027 call close

In two-stage topics, applicants first submit a short proposal, which is evaluated blind. Only applicants admitted to stage 2 submit a full proposal.

We have selected the topics below as potentially relevant to the pain research community. For full topic texts, eligibility conditions, and updates, please refer to the Health Work Programme 2026-2027 and the Funding & Tenders Portal.

Destination: Staying healthy in a rapidly changing society

HORIZON-HLTH-2027-01-STAYHLTH-01

Addressing disabilities through the life course to support independent living and inclusion

RIASingle-stage
Funder
European Commission - Horizon Europe (Cluster 1: Health), Destination "Staying healthy in a rapidly changing society"
Type of action
Research and Innovation Action (RIA)
Submission model
Single-stage
Submission deadline
17 February 2027, 17:00 Brussels timeCheck the Funding & Tenders Portal for updates.
Budget
Total indicative budget €39.3 million; expected EU contribution per project €6-8 million (lump sum); around 5 projects

Aims / Objectives

This topic supports research that enables persons with long-term physical, mental, intellectual, or sensory disabilities to live independently and participate fully in their communities throughout the life course. Proposals must address at least three of the following areas:

  • health conditions leading to or associated with disabilities, including innovative diagnostic, therapeutic, technological, or low-tech solutions;
  • children with disabilities, young people transitioning to adulthood, and/or older persons;
  • access to prehabilitation and rehabilitation, including psychological rehabilitation and assistive technologies;
  • prevention of disabilities across the life course, considering health, behavioural, and socio-economic factors;
  • transitions from institutional settings to community living;
  • person-centred care models that support autonomy, self-care, and different care choices.

Persons with disabilities are expected to take part in the research as actors, through their representative organisations.

Relevance to the pain community

Chronic pain is one of the largest contributors to disability in Europe, and low back pain has ranked as the leading global cause of years lived with disability in successive Global Burden of Disease studies. Several of the topic's core areas reflect established priorities in pain care: rehabilitation, psychological approaches, prevention, and person-centred care models. Pain research groups working on chronic pain and functioning, on transitions from paediatric to adult services, or on pain in older adults are well placed to contribute. Its emphasis on co-creation also suits consortia that involve patient organisations from the outset.

For example, A proposal could co-design and evaluate community-based rehabilitation with people whose chronic pain limits daily activities, focusing on independent living and participation in work, education or community life.

Destination: Tackling diseases and reducing disease burden

HORIZON-HLTH-2027-01-DISEASE-10

Prevention and management of chronic non-communicable diseases in children and young people (GACD)

RIASingle-stage
Funder
European Commission - Horizon Europe (Cluster 1: Health), Destination "Tackling diseases and reducing disease burden"
Type of action
Research and Innovation Action (RIA)
Submission model
Single-stage
Submission deadline
17 February 2027, 17:00 Brussels timeCheck the Funding & Tenders Portal for updates.
Budget
Total indicative budget €11.8 million; expected EU contribution per project €3-4 million (lump sum); around 3 projects

Aims / Objectives

This topic is launched with the Global Alliance for Chronic Diseases (GACD) and funds implementation research. Projects should improve prevention and management of chronic non-communicable diseases (NCDs) in children and young people aged 1 to 24, living in low- and middle-income countries and/or in underserved populations in high-income countries. Applicants may address any chronic NCD or combination of conditions, explicitly including mental health, musculoskeletal, and neurological conditions. Research may focus on:

  • screening and diagnosis of NCDs or risk factors, in particular using digital tools;
  • prevention strategies targeted at children and young people;
  • cost-effective, patient-centred management, including integrated care pathways and continuity of care for adolescents moving into adult services;
  • evaluation of policies addressing social, economic, structural, or commercial determinants of NCDs.

Proposals should use hybrid designs that measure both effectiveness and implementation outcomes. They should also collaborate meaningfully with young people and their families.

Relevance to the pain community

Chronic pain in childhood and adolescence is common and often persists into adulthood, yet few management strategies have been tested for these life stages. With musculoskeletal and neurological conditions explicitly in scope, this topic offers a route to implementation research on paediatric and adolescent pain, including transitions of care. Consortia must work with or in the eligible populations and should plan their partnerships accordingly.

For example, a proposal could study how to implement an evidence-based model care for persistent musculoskeletal pain in children and young people in low- and middle-income countries or underserved communities in high-income countries. It could involve digital and remote technologies.

Destination: Tackling diseases and reducing disease burden

HORIZON-HLTH-2027-02-DISEASE-01-two-stage

Innovative healthcare interventions for non-communicable diseases

RIATwo-stage
Funder
European Commission - Horizon Europe (Cluster 1: Health), Destination "Tackling diseases and reducing disease burden"
Type of action
Research and Innovation Action (RIA)
Submission model
Two-stage
Submission deadlines
Stage 1: 17 February 2027Stage 2: 16 September 2027Both 17:00 Brussels time. Check the Funding & Tenders Portal for updates.
Budget
Total indicative budget €63.8 million; expected EU contribution per project €7-8 million (lump sum); around 8 projects

Aims / Objectives

This topic funds rigorous early-stage clinical trials that validate novel or refined healthcare interventions for treatment and disease management in four specific non-communicable diseases: cardiovascular diseases, diabetes, chronic respiratory diseases, and chronic kidney diseases. Other diseases are not in scope.

Interventions may be pharmacological and/or non-pharmacological, and pharmacological trials should be phase 1 and/or phase 2. Comparative effectiveness studies are excluded. At the time of submission, preclinical research and a draft clinical trial protocol should be complete, supported by proof-of-concept evidence of clinical safety and efficacy. Proposals should also:

  • address existing co- and multimorbidities in the trial design, wherever relevant;
  • use digital technologies, such as wearables, to implement and monitor the long-term efficacy of interventions;
  • engage patients, caregivers, clinicians, and regulators in designing interventions;
  • present a health-economic assessment and real-world data analysis to support sustainability and scalability.

Contributions from the social sciences and humanities are required.

Relevance to the pain community

Chronic pain frequently co-occurs with these four conditions. Painful diabetic peripheral neuropathy is a well-recognised complication of diabetes. Because the topic asks trials to address co- and multimorbidities and accepts non-pharmacological interventions, it offers a route for pain expertise within disease-specific consortia, for example on pain-related outcomes, multimodal disease management, and patient-reported measures. Proposals must be framed within one of the four eligible disease areas.

For example, pain researchers could help a trial in one of the four eligible diseases assess pain as a complication or coexisting condition, for example by measuring neuropathic pain in a trial of a new diabetes intervention.

Destination: Developing and using new tools, technologies and digital solutions for a healthy society

HORIZON-HLTH-2027-02-TOOL-01-two-stage

Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic non-communicable diseases

RIATwo-stage
Funder
European Commission - Horizon Europe (Cluster 1: Health), Destination "Developing and using new tools, technologies and digital solutions for a healthy society"
Type of action
Research and Innovation Action (RIA)
Submission model
Two-stage
Submission deadlines
Stage 1: 17 February 2027Stage 2: 16 September 2027Both 17:00 Brussels time. Check the Funding & Tenders Portal for updates.
Budget
Total indicative budget €44.2 million; expected EU contribution per project €6-8 million; around 6 projects

Aims / Objectives

This topic funds the clinical development of predictive biomarkers of disease progression and treatment response for chronic non-communicable diseases, excluding cancer.

Projects should adapt established AI methods rather than develop new ones. They should integrate currently used and candidate biomarkers with data from clinical studies, longitudinal cohorts, and real-world sources. Biomarkers should be multimodal, for example molecular, cellular, physiological, imaging, behavioural, or digital.

Projects are also expected to set up a validation platform for clinical utility and to develop a regulatory strategy. They should place strong emphasis on trustworthy AI, including the assessment of bias. The expected outcomes include:

  1. Clinical researchers have access to novel predictive biomarkers to assess disease progression and treatment response more accurately.
  2. Clinicians use clinically validated biomarkers to support personalised medicine and better health outcomes.
  3. Key stakeholders have access to trustworthy AI tools for developing multimodal biomarkers of higher clinical value than established practice.
  4. Citizens benefit from improved clinical guidelines and biomarker-guided care.

Relevance to the pain community

Chronic pain conditions are highly heterogeneous, and predicting who will develop persistent pain and who will respond to which treatment remain central open questions in the field. The explicit inclusion of behavioural and digital markers alongside molecular and imaging data fits a biopsychosocial understanding of pain. Applicants will need to justify the unmet clinical need for the condition under study. Chronic pain, now recognised in ICD-11, provides a strong basis for that case.

For example, a proposal could use new or established AI methods to develop and clinically validate multimodal biomarkers that predict which patients with a chronic pain condition are likely to respond to a specific treatment.

Destination: Tackling diseases and reducing disease burden

HORIZON-HLTH-2027-02-DISEASE-14-two-stage

Clinical trials for advancing innovative interventions for neurodegenerative diseases

RIATwo-stage
Funder
European Commission - Horizon Europe (Cluster 1: Health), Destination "Tackling diseases and reducing disease burden"
Type of action
Research and Innovation Action (RIA)
Submission model
Two-stage
Submission deadlines
Stage 1: 17 February 2027Stage 2: 16 September 2027Both 17:00 Brussels time. Check the Funding & Tenders Portal for updates.
Budget
Total indicative budget €39.3 million; expected EU contribution per project around €10 million; around 4 projects

Aims / Objectives

This topic funds rigorous early-stage clinical trials of innovative interventions for neurodegenerative diseases; for pharmacological interventions, this means phase 1 and/or phase 2. Rare neurodegenerative diseases are excluded. Therapies based on an active substance should be combined with a multidisciplinary approach, such as lifestyle changes, cognitive training, or rehabilitation. Proposals should:

  • gain insight into the mechanisms of action of the interventions;
  • use digital technologies such as wearables to monitor long-term efficacy and disease progression;
  • engage patients, caregivers, clinicians, and regulators in designing the interventions.

Contributions from the social sciences and humanities are required.

Relevance to the pain community

Pain is a frequent and often under-recognised non-motor symptom in conditions such as Parkinson's disease, and assessing pain in people living with dementia remains a recognised clinical challenge. The required combination of pharmacological and rehabilitation approaches matches multimodal pain management. Pain researchers and clinicians can strengthen consortia through expertise in pain assessment and pain-related outcomes.

For example, pain researchers could help an early-stage trial of a new intervention for Parkinson's disease assess whether it improves pain and how any change affects daily function.

Destination: Developing and using new tools, technologies and digital solutions for a healthy society

HORIZON-HLTH-2027-03-TOOL-08

Towards the next generation of frontier Artificial Intelligence models for healthcare

CSASingle-stageOpens 3 June 2027
Funder
European Commission - Horizon Europe (Cluster 1: Health), Destination "Developing and using new tools, technologies and digital solutions for a healthy society"
Type of action
Coordination and Support Action (CSA)
Submission model
Single-stage
Opening
3 June 2027
Submission deadline
16 September 2027, 17:00 Brussels timeCheck the Funding & Tenders Portal for updates.
Budget
Total indicative budget €2.9 million (lump sum); 1 project
Eligibility note
Participation is limited to legal entities established in EU Member States and Associated Countries.

Aims / Objectives

This coordination action will prepare the ground for the next generation of frontier AI models for healthcare. Activities include:

  • building a large-scale, multidisciplinary pan-European community of experts;
  • identifying, curating, and expanding the datasets best suited to developing frontier AI models;
  • mapping approaches to training and evaluating such models, including the use of the EU's AI Factories;
  • assessing the safety, efficacy, and risks of existing AI models with reference to the AI Act and to ethical and security considerations.

The main output will be a collaboratively developed roadmap for frontier AI models for healthcare.

Relevance to the pain community

This action shapes how future AI models for healthcare will be built, and which clinical areas and datasets they will draw on. Pain is complex and multidimensional, and AI models for healthcare need clinically realistic use cases of this kind. Organisations and experts in the pain field can contribute through the community-building and dataset identification activities, helping to ensure that pain is represented in the resulting roadmap.

For example, pain organisations could contribute to the European AI roadmap by identifying datasets that capture pain and its impact on daily life and proposing clinical use cases for model evaluation.

Working with EFIC

Include EFIC as a partner in your research consortia/grant applications

Funding bodies place increasing emphasis on the effective communication of results and on societal and clinical impact. EFIC can help your research project achieve this and more by:

Communicating your research project results and updates via EFIC's online communication channels: social media, mailing list, and website
Producing and sharing video interviews about your research
Hosting open webinars on your research
Connecting you to the programme organisers of our scientific meetings, where you may be offered the opportunity to showcase your research
Providing access to our database of 20,000 clinicians and researchers, including for survey participation
Recruiting subject matter experts through our Pain Scientist Network
Supporting patient and public involvement: involving patients and other stakeholders in your research through our strong links with patient organisations and our experience in lay-audience communication
Boosting your network through our established connections with scientific societies, industry, patient organisations, and policymakers

Please contact sam.kynman@efic.org for more information on how EFIC could contribute.

Email sam.kynman@efic.org
MENU